Based on these new findings, we further demonstrated that the combination of DC-targeted vaccines and anti-Tim-3 immune checkpoint blockade (ICB) improves the anti-tumor efficacy of DC vaccines. This evidence concerns the gene HAVCR2 and neoplasm.